Clinical Development Clinical Research Genomics Life Science 
Drug Discovery World
FEBRUARY 12, 2024
In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” It is becoming more broadly acknowledged that AI is set to transform one of the most promising yet under-utilised fields of omics – 3D genomics.
Drug Discovery World
OCTOBER 16, 2023
Maina Bhaman, Partner at Sofinnova Partners, says: “The UK is an attractive space for drug discovery companies and a prime environment for investment due to its talent, infrastructure, and genomics research. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JANUARY 17, 2024
Lupus, a complex autoimmune disease, has brought a substantial challenge to researchers and healthcare professionals. Understanding this condition and its various manifestations, as well as developing effective treatments, has been the focus of ongoing investigation in lupus clinical research for many years.
pharmaphorum
SEPTEMBER 12, 2022
Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. Tailored oncology.
The Pharma Data
NOVEMBER 5, 2020
Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D. Previously, he was an associate director at Navigant Life Science Consulting.
XTalks
APRIL 24, 2023
“Rare disease clinical trials are complex due to the additional scientific, medical, operational and regulatory requirements of newly emerging advanced therapies, such as gene therapy,” says Dr. Terence Eagleton, MB BS, Senior Medical Director at the global clinical research organization (CRO) Medpace.
pharmaphorum
OCTOBER 7, 2021
However, developments in genomic medicine are making huge strides to improve this situation, and these will also be discussed during the webinar. His academic and clinical focus is on benign haematology, where he has a particular interest in sickle cell disease, haemophilia and other rare blood disorders.
Expert insights. Personalized for you.
139 
Let's personalize your content